MX2009007008A - Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo. - Google Patents

Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.

Info

Publication number
MX2009007008A
MX2009007008A MX2009007008A MX2009007008A MX2009007008A MX 2009007008 A MX2009007008 A MX 2009007008A MX 2009007008 A MX2009007008 A MX 2009007008A MX 2009007008 A MX2009007008 A MX 2009007008A MX 2009007008 A MX2009007008 A MX 2009007008A
Authority
MX
Mexico
Prior art keywords
peptide
hla
amino acid
restricted
pharmaceutical composition
Prior art date
Application number
MX2009007008A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of MX2009007008A publication Critical patent/MX2009007008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se refiere a un péptido WT1 restringido a HLA-A*1101, específicamente un péptido que comprende una secuencia de aminoácidos que consiste en 9 aminoácidos contiguos provenientes de una proteína WT1, donde el péptido tiene la capacidad de unirse a una molécula HLA-A*1101 y tiene la capacidad de inducir un CTL; la presente invención también se refiere a un dímero de péptidos que tiene la capacidad de unirse a una molécula HLA-A*1101 y que tiene la capacidad de inducir un CTL, donde dos péptidos monómeros que comprenden cada uno una secuencia de aminoácidos que consiste en 9 aminoácidos contiguos de una proteína WT1 y que comprenden por lo menos un residuo de cisteína, se unen entre sí mediante un enlace bisulfuro; además, la presente invención se refiere a un polinucleótido que codifica el péptido, a una composición farmacéutica para el tratamiento y/o prevención de un cáncer que comprende el mismo y similares.
MX2009007008A 2006-12-28 2007-12-14 Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo. MX2009007008A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28
PCT/JP2007/074146 WO2008081701A1 (ja) 2006-12-28 2007-12-14 Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
MX2009007008A true MX2009007008A (es) 2009-07-10

Family

ID=39588385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007008A MX2009007008A (es) 2006-12-28 2007-12-14 Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.

Country Status (28)

Country Link
US (4) US8653038B2 (es)
EP (6) EP2341142B8 (es)
JP (1) JP5484734B2 (es)
KR (1) KR101525261B1 (es)
CN (5) CN102302788B (es)
AR (1) AR064555A1 (es)
AU (1) AU2007340679B2 (es)
BR (1) BRPI0720988A2 (es)
CA (5) CA2886622A1 (es)
CY (1) CY1116011T1 (es)
DK (3) DK2479275T3 (es)
ES (4) ES2629578T3 (es)
HK (3) HK1173187A1 (es)
IL (4) IL199052A0 (es)
MX (1) MX2009007008A (es)
MY (1) MY161664A (es)
NO (1) NO20092774L (es)
NZ (4) NZ592510A (es)
PH (1) PH12014500902B1 (es)
PL (1) PL2341142T3 (es)
PT (1) PT2341142E (es)
RU (1) RU2481398C2 (es)
SG (1) SG177222A1 (es)
SI (1) SI2341142T1 (es)
TW (3) TWI554280B (es)
UA (1) UA103154C2 (es)
WO (1) WO2008081701A1 (es)
ZA (1) ZA200903633B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
AU2008220031B2 (en) 2007-02-27 2013-06-13 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
AU2011313327B2 (en) * 2010-10-05 2015-10-22 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
CN106632677B (zh) * 2011-04-01 2021-10-26 纪念斯隆-凯特琳癌症中心 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
BR112014002747A2 (pt) 2011-09-14 2020-10-27 International Institute Of Cancer Immunology, Inc método para medir um anticorpo anti-wt1
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN104797711B (zh) 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
EP2931949B1 (en) 2012-12-11 2019-09-18 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
SG10201705028WA (en) * 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
RU2687026C2 (ru) 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
CN103961699B (zh) 2013-02-05 2018-11-06 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CA2840937A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
KR102050931B1 (ko) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
RU2687144C2 (ru) 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения
CA2840974A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
EP3461493A1 (en) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
WO2014157704A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
KR20170092660A (ko) 2014-12-11 2017-08-11 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US20190352363A1 (en) 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2018234628B2 (en) 2017-03-15 2023-07-20 Cue Biopharma, Inc. Methods for modulating an immune response
JPWO2019131722A1 (ja) * 2017-12-27 2021-01-14 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
CN116096405A (zh) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 多聚体t细胞调节多肽及其使用方法
KR20230009426A (ko) * 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
IL142216A0 (en) * 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
ATE399793T1 (de) * 1999-04-02 2008-07-15 Corixa Corp Verbindungen und verfahren für therapie und diagnose von lungenkrebs
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
BRPI0208183B8 (pt) * 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
AU2003242305A1 (en) 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
CN100421665C (zh) * 2002-06-14 2008-10-01 麦克公司 有丝***驱动蛋白抑制剂
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
AU2004204031B2 (en) 2003-01-15 2010-03-04 International Institute Of Cancer Immunology, Inc. Dimerized peptide
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
WO2005095598A1 (ja) 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Also Published As

Publication number Publication date
CN101573448A (zh) 2009-11-04
MY161664A (en) 2017-04-28
EP2098595A4 (en) 2010-03-17
AU2007340679A1 (en) 2008-07-10
TW201345544A (zh) 2013-11-16
DK2479275T3 (en) 2015-12-14
CA2886622A1 (en) 2008-07-10
ES2526425T3 (es) 2015-01-12
US8653038B2 (en) 2014-02-18
IL215334A0 (en) 2011-11-30
DK2479276T3 (en) 2015-12-21
RU2009128979A (ru) 2011-02-10
EP2341142A2 (en) 2011-07-06
NZ592510A (en) 2012-11-30
AU2007340679B2 (en) 2013-09-12
CN102302788B (zh) 2016-06-15
ES2556831T3 (es) 2016-01-20
PH12014500902A1 (en) 2016-01-11
US9272026B2 (en) 2016-03-01
EP2479275B1 (en) 2015-10-28
EP3026115A1 (en) 2016-06-01
TWI417103B (zh) 2013-12-01
US20110098233A1 (en) 2011-04-28
PL2341142T3 (pl) 2015-04-30
EP2980219A1 (en) 2016-02-03
KR20090102772A (ko) 2009-09-30
CA2886621A1 (en) 2008-07-10
CN102335439A (zh) 2012-02-01
SI2341142T1 (sl) 2015-03-31
ZA200903633B (en) 2010-02-24
NZ577443A (en) 2011-12-22
EP2980219B1 (en) 2018-11-14
AR064555A1 (es) 2009-04-08
HK1173187A1 (zh) 2013-05-10
CY1116011T1 (el) 2017-01-25
CN102659924B (zh) 2015-11-25
IL215333A0 (en) 2011-11-30
CN102302788A (zh) 2012-01-04
KR101525261B1 (ko) 2015-06-02
US20140134200A1 (en) 2014-05-15
US20160199472A1 (en) 2016-07-14
IL199052A0 (en) 2010-03-28
EP2341142B1 (en) 2014-11-26
CA2886620A1 (en) 2008-07-10
NZ592509A (en) 2012-11-30
EP2479276A1 (en) 2012-07-25
JPWO2008081701A1 (ja) 2010-04-30
TW201630620A (zh) 2016-09-01
DK2341142T3 (en) 2014-12-08
RU2481398C2 (ru) 2013-05-10
HK1159686A1 (en) 2012-08-03
TW200835513A (en) 2008-09-01
EP3026115B1 (en) 2017-05-17
CA2886619A1 (en) 2008-07-10
NZ601175A (en) 2012-12-21
EP2098595A1 (en) 2009-09-09
UA103154C2 (uk) 2013-09-25
NO20092774L (no) 2009-07-27
EP2341142A3 (en) 2011-09-07
EP2341142B8 (en) 2015-01-14
EP2479276B1 (en) 2015-12-09
CN102295682A (zh) 2011-12-28
CA2670658A1 (en) 2008-07-10
TWI554280B (zh) 2016-10-21
PH12014500902B1 (en) 2016-01-11
EP2479275A1 (en) 2012-07-25
US20180064795A1 (en) 2018-03-08
JP5484734B2 (ja) 2014-05-07
ES2554775T3 (es) 2015-12-23
PT2341142E (pt) 2015-02-13
BRPI0720988A2 (pt) 2014-03-18
CN102659924A (zh) 2012-09-12
ES2629578T3 (es) 2017-08-11
CN102335439B (zh) 2015-04-22
HK1221252A1 (zh) 2017-05-26
CN101573448B (zh) 2012-07-11
IL215332A0 (en) 2011-11-30
TWI599367B (zh) 2017-09-21
WO2008081701A1 (ja) 2008-07-10
SG177222A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
MX2009007008A (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
CY1113117T1 (el) Ηlα-α*3303-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση η οποια περιλαμβανει αυτο το ιδιο
BRPI0413276B8 (pt) derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
BRPI0718996B8 (pt) método para a preparação de um peptídio da fórmula h-d-?-nal-[cys-tyr-d-trp-lys-val-cys]-thr-nh2 ou h-d-?-nal-cys(acm)-tyr-d-trp-lys-val-cys(acm)-thr
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
IL173969A0 (en) Use of peptides derived from the a alpha or b beta chain of human of human fibrinogen for the treatment of shock
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
MX2011012742A (es) Compuestos depuradores de metilglioxal y su uso para la prevencion y tratamiento de dolor y/o hiperalgesia.
MX2020010520A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas.
WO2010011994A3 (en) Polypeptides and uses thereof
WO2006097748A3 (en) Peptide stabilizer compounds and screening method
MY126118A (en) Somatostatin analogs for the treatment of cancer
EP3771719A8 (en) A peptide binding to tau-protein
EP1915617A4 (en) METHOD AND COMPOSITIONS FOR IDENTIFYING A PEPTIDE WITH INTERMOLECULAR INTERACTION WITH AN INTERESTING OBJECTIVE
EP1730174A4 (en) PEPTIDE CARRIER FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
ATE291587T1 (de) Somatostatin analoge und deren verwendung zur behandlung von krebs
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Legal Events

Date Code Title Description
FG Grant or registration